Peptonic Medical

VagiVital® AktivGel is a treatment for vaginal atrophy and was the first product that Peptonic launched in intimate care. Peptonic intends to be a leading player in clinically proven intimate self-care, and there is a clear trend that people want to take greater responsibility for their own health with clinically proven self-care products. 

"The need for and interest in VagiVital® AktivGel continues to grow, and we are pleased that Apotek Hjärtat now chooses to bring our product into its stores as well. This means that we strengthen our position in the important Swedish home market," said Erik Sundquist, CEO of Peptonic Medical.

VagiVital® AktivGel is already sold online by all Swedish pharmacy operators and in all physical pharmacies with the exception of Apotek Hjärtat. The market for this type of treatment is growing by about 10% per year. In 2022, VagiVital AktivGel grew by more than +50% in Sweden compared to 2021 and increased its market share significantly, a growth that also forms the basis for Apotek Hjärtat's decision to now bring VagiVital® AktivGel into ca 300 of its 400 physical stores, which represent just under 30% of the total number of physical pharmacies in Sweden.

"The fact that distribution is now being expanded to the majority of Apotek Hjärtat's physical pharmacies is an important and significant step for continued rapid sales growth and increased distribution of Peptonic's products in the important home market in Sweden," said Erik Sundquist.